Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy Eur J Allergy Clin Immunol. 2014;69:868–87.
   Google Scholar
• Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing and management of chronic inducible urticarias – update and revision of the EAACI/GA 2 LEN/EDF/UNEV 2009 consensus panel recommendations. Allergy. 2016;71:780–802.
   PubMed Web of Science ®Google Scholar
• Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:337–42.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Pigatto P, Cristaudo A, et al. Management of chronic spontaneous urticaria: practical parameters. G Ital Dermatol Venereol. 2015;150:237–46.
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012;4:326–31.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
   Google Scholar
• Engin B, Ozdemir M, Balevi A, Mevlitoğlu I. Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial. Acta Derm Venereol. 2008;88:247–51.
   PubMed Web of Science ®Google Scholar
• Sagi L, Solomon M, Baum S, et al. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol. 2011;91:303–6.
   PubMed Web of Science ®Google Scholar
• Raghavendran RR, Humphreys F, Kaur MR. Successful use of mycophenolate mofetil to treat severe chronic urticaria in a patient intolerant to ciclosporin. Clin Exp Dermatol. 2014;39:68–9.
   PubMed Web of Science ®Google Scholar
• Tal Y, Toker O, Agmon-Levin N, Shalit M. Azathioprine as a therapeutic alternative for refractory chronic urticaria. Int J Dermatol. 2015;54:367–9.
   PubMed Web of Science ®Google Scholar
• Kibsgaard L, Lefevre AC, Deleuran M, Vestergaard C. A case series study of eighty-five chronic spontaneous urticaria patients referred to a tertiary care center. Ann Dermatol. 2014;26:73–8.
   PubMed Web of Science ®Google Scholar
• Adamski H, Bedane C, Bonnevalle A, et al. Solar urticaria treated with intravenous immunoglobulins. J Am Acad Dermatol. 2011;65:336–40.
   PubMed Web of Science ®Google Scholar
• Orden RA, Timble HSS. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2014;112:64–70.
   PubMed Web of Science ®Google Scholar
• Pho LN1, Eliason MJ, Regruto M, Hull CMPD. Treatment of chronic urticaria with colchicine. J Drugs Dermatol. 2011;10:1423–8.
   PubMed Web of Science ®Google Scholar
• Reeves GEM, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J. 2004;34:182–6.
   PubMed Web of Science ®Google Scholar
• Kulthanan KTN. Positive impact of chloroquine on delayed pressure urticaria. J Drugs Dermatol. 2007;6:445–6.
   PubMedGoogle Scholar
• Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol. 1977;47:369–70.
   Google Scholar
• Grattan CE, Francis DM, Slater NG, Barlow RJGM. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339:1078–80.
   PubMed Web of Science ®Google Scholar
• Bishnoi A, Parsad D, Vinay K, Kumaran MS. Phototherapy using NB-UVB and PUVA is beneficial in steroid dependent antihistamine refractory chronic urticaria: a randomized prospective observer blinded comparative study. Br J Dermatol. 2017;176:62–70.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55:705–9.
   PubMed Web of Science ®Google Scholar
• Erxun K, Wei L, Shuying Q. Kounis syndrome caused by chronic autoimmune urticaria: a case report. J Emerg Med. 2015.
   PubMed Web of Science ®Google Scholar
• Ghoshal L, Das S, Das S, et al. Azathioprine in autologous serum skin test positive chronic urticaria: a case-control study in a tertiary care hospital of eastern India. Indian Dermatol Online J. 2015;6:185.
   PubMedGoogle Scholar
• Koranda FCM. Antimalarials. J Am Acad Dermatol. 1981;4:650–5.
   PubMedGoogle Scholar
• Lopez LI, Davis KC, Kohler PF, et al. The hypocomplementemic syndrome: Therapeutic hydroxychloroquine response to. J Allergy Clin Immunol. 1984;73:600–3.
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Peroni A, Schena D, Girolomoni G. Preheated autologous serum skin test in localized heat urticaria. Clin Exp Dermatol. 2014;39:921–3.
   PubMed Web of Science ®Google Scholar
• Borradori L, Rybojad M, Weiss L, et al. Chronic urticaria and acquired complement deficiency due to a nephritic factor (C3NeF). Schweiz Med Wochenschr. 1990;25:1236–41. Aug
   Google Scholar
• Criado RFJ, Criado PR, Martins JEC, et al. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat. 2008;19:92–6.
   PubMed Web of Science ®Google Scholar
• Asero R. Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:1401–3.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.
   PubMed Web of Science ®Google Scholar
• Noda S, Asana YSS. Long-term complete resolution of severe chronic idiopathic urticaria after dapsone treatment case of necrobiosis lipoidica diabeticorum successfully treated by photodynamic therapy. J Dermatol. 2011;496–7.
   PubMedGoogle Scholar
• Clarindo MV, Soligo EM, Ruaro RT, et al. Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment. An Bras Dermatol. 2014;89:865–77.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15:962–9.
   PubMed Web of Science ®Google Scholar
• Kar HK, Gupta R. Treatment of leprosy. Clin Dermatol. 2015;33:55–65.
   PubMed Web of Science ®Google Scholar
• Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect. 2015;45:383–93.
   PubMed Web of Science ®Google Scholar
• Sameem FS, Wafai Z, Zulfkar Q. Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria. Indian J Pharmacol. 2014;46:438.
   PubMed Web of Science ®Google Scholar
• Do Valle SOR, França AT, Pires GV, et al. Dapsone hypersensitivity syndrome during delayed pressure urticaria treatment. Ann Allergy Asthma Immunol. 2010;104:181–2.
   PubMed Web of Science ®Google Scholar
• Grundmann SA, Kiefer S, Luger TA, Brehler R. Delayed pressure urticaria – dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011;9:908–12.
   PubMed Web of Science ®Google Scholar
• Engin B, Ozdemir M. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol. 2008;22:481–6.
   PubMed Web of Science ®Google Scholar
• Aubin F, Porcher R, Jeanmougin M, et al. Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study. J Am Acad Dermatol. 2014;71:948–53.
   PubMed Web of Science ®Google Scholar
• Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol. 2007;39:237–42.
   PubMedGoogle Scholar
• Perez a, Woods A, Grattan CEH. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol. 2010;162:191–4.
   PubMed Web of Science ®Google Scholar
• Sharma V, Singh S, Ramam M, et al. A randomized placebo-controlled double-blind pilot study of methotrexate in the treatment of H1 antihistamine-resistant chronic spontaneous urticaria. Indian J Dermatol Venereol Leprol. 2014;80:122–8.
   PubMed Web of Science ®Google Scholar
• Minciullo PL, Saija A, Bonanno D, et al. Montelukast-induced generalized urticaria. Ann Pharmacother. 2004;38:999–1001.
   PubMed Web of Science ®Google Scholar
• Levi A, Enk CD. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity. Photodermatol Photoimmunol Photomed. 2015;31:302–6.
   PubMed Web of Science ®Google Scholar
• Wan KS, Chang YS. Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria. J Dermatolog Treat. 2014;25:459–61.
   PubMed Web of Science ®Google Scholar
• Pacor MLDLG, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double‐blind, placebo‐controlled comparison of treatment with montelukast and cetirizine in patients. Clin Exp Allergy. 2001;31:1607–14.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114:619–25.
   PubMed Web of Science ®Google Scholar
• Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol. 2002;110:484–8.
   PubMed Web of Science ®Google Scholar
• Mora PM, González C, Villarruel MJ, et al. Artículo original opciones terapéuticas en urticaria crónica idiopática. Rev Alerg México. 2005;52:77–82.
   PubMedGoogle Scholar
• Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34:1401–7.
   PubMed Web of Science ®Google Scholar
• Nettis E, Colanardi MC, Soccio AL, et al. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2006;155:1279–82.
   PubMed Web of Science ®Google Scholar
• Zimmerman AB, Berger EM, Elmariah SB, Soter NA. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol. 2012;66:767–70.
   PubMed Web of Science ®Google Scholar
• Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol. 2006;45:1224–7.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Kawakami T, Ishii N, et al. Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria. Dermatol Ther. 2012;25:379–81.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Buskard N, McLean DILH. Treatment of refractory solar urticaria with plasma exchange. J Cutan Med Surg. 1999;3:236–8.
   Google Scholar
• Collins P, Ahamat R, Green C, Ferguson J. Plasma exchange therapy for solar urticaria. Br J Dermatol. 1996;134:1093–7.
   PubMed Web of Science ®Google Scholar
• Jaffer AM, MDC. Brief communications sulfasalazine in the treatment of chronic idiopathic urticaria validity of skin tests to cyclophosphamide and metabolites. J Allergy Clin Immunol. 1991;88:964–5.
   PubMed Web of Science ®Google Scholar
• McGirt LY, Vasagar K, Gober LM, et al. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol. 2006;142:1337–42.
   PubMedGoogle Scholar
• Bouillet L, Ponard D, Drouet C, Massot C. Interet diagnostic et therapeutique de l’acide tranexamique dans les angio-oedemes non-histaminiques. La Rev Med Interne. 2004;25:924–6.
   PubMedGoogle Scholar
• Asero R, Tedeschi ACM. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated D-dimer: a pilot study. Int Arch Allergy Immunol. 2010;152:384–9.
   PubMed Web of Science ®Google Scholar
• Shedden C, Highet AS. Delayed pressure urticaria controlled by tranexamic acid. Clin Exp Dermatol. 2006;31:295–6.
   PubMed Web of Science ®Google Scholar
• Martens B. Clinical experience with tranexamic acid (cyclocapron) in urticaria and angio-oedema. Br J Dermatol. 1984;111:481–2.
   Web of Science ®Google Scholar
• Tant D. Tranexamic acid in chronic urticaria. Br Med J. 1979;1:266.
   PubMedGoogle Scholar
• Uetsu N, Miyauchi-Hashimoto H, Okamoto H, Horio T. The clinical and photobiological characteristics of solar urticaria in 40 patients. Br J Dermatol. 2000;142:32–8.
   PubMed Web of Science ®Google Scholar
• Aydogan K, Karadogan S. Narrowband ultraviolet B (311 nm, TL01) phototherapy in chronic ordinary urticaria. Int J Dermatol. 2012;51:98–103.
   PubMed Web of Science ®Google Scholar
• Du-Thanh A, Debu A, Lalheve P, et al. Solar urticaria: a time-extended retrospective series of 61 patients and review of literature. Eur J Dermatol. 2013;23:202–7.
   PubMed Web of Science ®Google Scholar
• Urgert MC, Elzen MT, Van Den Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173:404–15.
   PubMed Web of Science ®Google Scholar
• Silva PM, Costa A C, Mendes A, Barbosa MP. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015;43:168–73.
   PubMed Web of Science ®Google Scholar
• Trojan TD, Khan DA. Calcineurin inhibitors in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12:412–20.
   PubMed Web of Science ®Google Scholar
• Mitchell S, Balp MM, Samuel M, et al. Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int J Dermatol. 2015;54:1088–104.
   PubMed Web of Science ®Google Scholar
• Hughes R, Cusack C, Murphy GM, Kirby B. Solar urticaria successfully treated with intravenous immunoglobulin. Clin Exp Dermatol. 2009;34:2008–10.
   Web of Science ®Google Scholar
• Chow SKW. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy. 2012;2:149–60.
   PubMedGoogle Scholar
• Khafagy NH, Salem SAM, Ghaly EG. Comparative study of systemic psoralen and ultraviolet A and narrowband ultraviolet B in treatment of chronic urticaria. Photodermatol Photoimmunol Photomed. 2013;29:12–17.
   PubMed Web of Science ®Google Scholar
• Khan S, Maitra A, Hissaria P, et al. Chronic urticaria: Indian context – challenges and treatment options. Dermatol Res Pract. 2013;2013:651737.
   PubMedGoogle Scholar
• Stotland M, Shalita AR, Kissling RF. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. Am J Clin Dermatol. 2009;10:221–7.
   PubMed Web of Science ®Google Scholar
• Kannan G, Vasantha J, Rani NV, et al. Drug usage evaluation of dapsone. Indian J Pharm Sci. 2009;71:456–60.
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Ayre G, Martin C, et al. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy Eur J Allergy Clin Immunol. 2008;63:409–17.
   Google Scholar
• Fine LM, Bernstein JA. Guideline of chronic urticaria beyond. Allergy Asthma Immunol Res. 2016;8:396–403.
   PubMed Web of Science ®Google Scholar
• Ensina LF, De Lacerda AE, Machado LMDO, et al. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience. Ann Allergy Asthma Immunol. 2015;115:536.
   PubMed Web of Science ®Google Scholar
• Asero R. Are IVIG for chronic unremitting urticaria effective?. Allergy. 2000;55:1099–101.
   PubMed Web of Science ®Google Scholar
• Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5:125–47.
   PubMedGoogle Scholar
• Belani HM, Gensler LM, Bajpai U, MDP, et al. Neutrophilic Urticaria With Systemic inflammation: a case series. JAMA Dermatol. 2013;149:453–8.
   PubMed Web of Science ®Google Scholar
• Lawlor F, Black AK, Ward AM, Morris RGM. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol. 1989;120:403–8.
   PubMed Web of Science ®Google Scholar
• Hurabielle C, Bedane C, Avenel-Audran M, et al. No major effect of cyclosporin A in patients with severe solar urticaria: a French retrospective case series. Acta Derm Venereol. 2015;95:1030–1.
   PubMed Web of Science ®Google Scholar
• Neverman L, Weinberger M. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract. 2014;2:434–8.
   PubMed Web of Science ®Google Scholar
• Guaragna MA, Albanesi M, Alfieri S, et al. Chronic urticaria with high IgE levels: first results on oral cyclosporine A treatment. Clin Ter. 2013;164:115–18.
   PubMed Web of Science ®Google Scholar
• Toda S, Takahagi S, Mihara S, Hide M. Six cases of antihistamine-resistant dermographic urticaria treated with oral ciclosporin. Allergol Int. 2011;60:547–50.
   PubMedGoogle Scholar
• Di Leo E, Nettis E, Aloia A, et al. Cyclosporin-A efficacy in chronic idiopathic urticaria. Int J Immunopathol Pharmacol. 2011;24:195–200.
   Google Scholar
• Kessel a, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy Eur J Allergy Clin Immunol. 2010;65:1478–82.
   Google Scholar
• Ohtsuka T. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int J Dermatol. 2010;49:579–84.
   PubMed Web of Science ®Google Scholar
• Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26:409–13.
   PubMed Web of Science ®Google Scholar
• Ju HY, Kim HS, Kim HO, Park YM. Cyclosporine treatment in a patient with concurrent autoimmune urticaria and autoimmune hepatitis. Ann Dermatol. 2009;21:291–3.
   PubMed Web of Science ®Google Scholar
• Serhat Inaloz H, Ozturk S, Akcali C, et al. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol. 2008;35:276–82.
   PubMed Web of Science ®Google Scholar
• Giuliodori K, Ganzetti G, Campanati A, et al. A non-responsive chronic autoimmune urticaria in a 12-year-old autistic girl treated with cyclosporin. J Eur Acad Dermatol Venereol. 2009;23:619–20.
   PubMed Web of Science ®Google Scholar
• Kessel ATE. Extended cyclosporine-A-treatment for severe chronic urticaria. Harefuah. 2006;145:411–14.
   PubMedGoogle Scholar
• Bulbul Baskan STE, Saricaoglu TT, H. Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria. J Dermatolog Treat. 2004;15:164–8.
   PubMedGoogle Scholar
• Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc. 2003;24:285–90.
   PubMed Web of Science ®Google Scholar
• E, Toubi E, Bamberger AK. Prolonged cyclosporin-A treatment for severe chronic urticaria. Allergy. 2003;58:535–6.
   PubMed Web of Science ®Google Scholar
• Loria MP, Dambra PP, Nettis E, et al. Cyclosporin a in Patients Affected By Chronic Idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol. 2001;23:205–13.
   Google Scholar
• Nilsel I, Mehmet AG, Mehmet AA. Short-term oral cyclosporine for chronic idiopathic urticaria. JEADV. 1993;9959:67–68.
   Google Scholar
• Edstrom D, Ros A. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed. 1997;13:61–3.
   PubMed Web of Science ®Google Scholar
• Morgan M, Cooke A, Rogers L, et al. Double-blind placebo controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol Pr. 2008;15:1203–14.
   Google Scholar
• Highlights J, Commentary regarding trial of dapsone in antihistamine refractory chronic idiopathic urticaria by M Morgan, A Cooke, L Rogers, B Adams-Huet, DA Khan. J Allergy Clin Immunol. 2015;28:102–103.
   Google Scholar
• Cassano N, D’Argento V, Filotico R, Vena GA. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol. 2005;85:254–5.
   PubMed Web of Science ®Google Scholar
• Boehm R, Bauer R, Bieber T. Urticaria treated with dapsone. Allergy. 1999;54:765–6.
   PubMed Web of Science ®Google Scholar
• Jandus P, Hausmann O, Pichler WJ, Helbling A. Intravenous immunoglobulin in urticaria. J Investig Allergol Clin Immunol. 2013;23:71–3.
   PubMed Web of Science ®Google Scholar
• Llamas-velasco M, Argila D, De Eguren C, et al. Solar urticaria unresponsive to intravenous immunoglobulins. Photodermatol Photoimmunol Photomed. 2011;27:53–4.
   PubMed Web of Science ®Google Scholar
• Hrabak T, Calabria CW. Multiple treatment cycles of high-dose intravenous immunoglobulin for chronic spontaneous urticaria. Ann Allergy, Asthma Immunol. 2010;105:245.
   PubMed Web of Science ®Google Scholar
• Mitzel-Kaoukhov H, Staubach P, Müller-Brenne T. Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2010;104:253–8.
   PubMed Web of Science ®Google Scholar
• Maksimovic L, Frémont G, Jeanmougin M, et al. Solar urticaria successfully treated with intravenous immunoglobulins. Dermatology (Basel). 2009;218:252–4.
   PubMed Web of Science ®Google Scholar
• Correia I, Silva J, Filipe P, Gomes M. Solar urticaria treated successfully with intravenous high-dose immunoglobulin: a case report. Photodermatol Photoimmunol Photomed. 2008;24:330–1.
   PubMed Web of Science ®Google Scholar
• Ségard MD, Mortier L, Bonnevalle ATP. Treatment of solar urticaria by intravenous immunoglobulins and PUVA therapy. Ann Dermatol Venereol. 2004;131:65–9.
   PubMed Web of Science ®Google Scholar
• Dawn G, Urcelay M, Ah-Weng A, et al. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol. 2003;149:836–40.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Vogt T, Landthaler M, Stolz W. The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol. 2000;80:225.
   PubMed Web of Science ®Google Scholar
• Puech-Plottova I, Michel JL, Rouchouse B, et al. Solar urticaria: one case treated by intravenous immunoglobulin. Ann Dermatol Venereol. 2004;127:831–5.
   Google Scholar
• O’Donnell BF, Barr RM, Kobza Black A, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138:101–6.
   PubMed Web of Science ®Google Scholar
• Godse K. Methotrexate in autoimmune urticaria. Indian J Dermatol Venereol Leprol. 2004;70:377.
   PubMedGoogle Scholar
• Mora PM. Artículo original Urticaria autoinmunitaria. Tratamiento Con Metotrexato. 2004;51:167–73.
   Google Scholar
• Gach JE, Sabroe RA, Greaves MW, Black a. K. Methotrexate-responsive chronic idiopathic urticaria: a report of two cases. Br J Dermatol. 2001;145:340–3.
   PubMed Web of Science ®Google Scholar
• Weiner MJ. Methotrexate in corticosteroid-resistant urticaria. Ann Intern Med. 1989;11:848.
   Google Scholar
• Antolín-Amérigo D, Vlaicu PC, Caballer BDLH, Cano MS. Anaphylaxislike cholinergic urticaria. Can Fam Physician. 2013;59:745–6.
   PubMed Web of Science ®Google Scholar
• Khan SLN. Efficacy of montelukast as added therapy in patients with chronic idiopathic urticaria. Inflamm Allergy Drug Targets. 2012;11:235–43.
   PubMedGoogle Scholar
• Kosnik M, Subic T. Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med. 2011;105:S84–S8.
   PubMed Web of Science ®Google Scholar
• A T. Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. Eur Ann Allergy Clin Immunol. 2009;41:187–9.
   PubMedGoogle Scholar
• Y, Berkun MS. Successful treatment of delayed pressure urticaria with montelukast. J Allergy Clin Immunol. 2007;119:203–4.
   Web of Science ®Google Scholar
• Feinberg JH, Toner CB. Successful treatment of disabling cholinergic urticaria. Mil Med. 2008;173:217–20.
   PubMed Web of Science ®Google Scholar
• Goel A, Prasad D. Oral monteleukast in urticaria induced by nonsteroidal anti-inflammatory drugs. J Eur Acad Dermatol Venereol. 2007;21:1275–6.
   PubMed Web of Science ®Google Scholar
• Godse K. Oral montelukast monotherapy is ineffective in chronic idiopathic urticaria: a comparison with oral cetirizine. Indian J Dermatol Venereol Leprol. 2006;72:312–14.
   PubMedGoogle Scholar
• Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005;297:134–8.
   PubMed Web of Science ®Google Scholar
• Vita D, Passalacqua G, Caminiti L, et al. Successful combined therapy for refractory chronic urticaria in a 10-year-old boy. Allergy. 2004;59:1021–2.
   PubMed Web of Science ®Google Scholar
• Nettis E, Pannofino E, Cavallo E, et al. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol. 2003;112:212–13.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Lorini M. Leukotriene receptor antagonists in chronic urticaria. Allergy. 2001;56:456–7.
   PubMed Web of Science ®Google Scholar
• Hani N, Hartmann K, Casper C, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist copyright of acta dermato-venereologica is the property of Society for Publication of Acta Dermato-Venereologica and its content may not be copied or emailed to multiples. Acta Derm Venereol. 2000;80:229.
   PubMed Web of Science ®Google Scholar
• Insawang MWC, Recalcitrant solar urticaria induced by UVA and visible light: a case report.
   Google Scholar
• Jiang X, Lu M, Ying Y, et al. A case report of double-filtration plasmapheresis for the resolution of refractory chronic urticaria. Ther Apher Dial. 2008;12:505–8.
   PubMed Web of Science ®Google Scholar
• Hudson Peacock M. Combined treatment of solar urticaria with plasmapheresis and PUVA. Br J Dermatol. 1993;128:440–2.
   PubMed Web of Science ®Google Scholar
• Leenutaphong V, Hölzle E, Plewig G, Kutkuhn BGB. Plasmapheresis in solar urticaria. Dermatologica. 1991;182:35–8.
   PubMedGoogle Scholar
• Duschet P, Leyen P, Schwarz T, et al. Solar urticaria: treatment by plasmapheresis. J Am Acad Dermatol. 1986;15:712–3.
   PubMed Web of Science ®Google Scholar
• Swerlick RA, Puar N. Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients. Dermatol Ther. 2015;28:318–22.
   PubMed Web of Science ®Google Scholar
• Hartmann K, Hani N, Hinrichs R, et al. Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria. Acta Derm Venereol. 2001;81:71.
   PubMed Web of Science ®Google Scholar
• Engler RJ, Squire EBP. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol. 1995;74:155–9.
   PubMed Web of Science ®Google Scholar
• Masuoka E, Fukunaga A, Kishigami K, et al. Successful and long-lasting treatment of solar urticaria with ultraviolet A rush hardening therapy. Br J Dermatol. 2012;167:198–201.
   PubMed Web of Science ®Google Scholar
• Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed. 2008;24:19–23.
   PubMed Web of Science ®Google Scholar
• Treudler R, Tebbe B, Steinhoff MOC. Familial aquagenic urticaria associated with familial lactose intolerance. J Am Acad Dermatol. 2002;47:611–3.
   PubMed Web of Science ®Google Scholar
• Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42:1030–2.
   PubMed Web of Science ®Google Scholar
• Addo HASS. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. Br J Dermatol. 1987;116:539–47.
   PubMed Web of Science ®Google Scholar
• Hölzle E, Hofmann CPG. PUVA-treatment for solar urticaria and persistent light reaction. Arch Dermatol Res. 1980;269:87–91.
   PubMed Web of Science ®Google Scholar
• Wolf R, Herzinger T, Grahovac M, Prinz JC. Solar urticaria: long-term rush hardening by inhibition spectrum narrow-band UVB 311 nm. Clin Exp Dermatol. 2013;38:446–7.
   PubMed Web of Science ®Google Scholar
• Calzavara-Pinton P, Zane C, Rossi M, et al. Narrowband ultraviolet B phototherapy is a suitable treatment option for solar urticaria. J Am Acad Dermatol. 2012;67:5–9.
   Web of Science ®Google Scholar
• Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. J Am Acad Dermatol. 2008;59:752–7.
   PubMed Web of Science ®Google Scholar
• Hannuksela MKE. Ultraviolet light therapy in chronic urticaria. Acta Derm Venereol. 1985;65:449–50.
   PubMed Web of Science ®Google Scholar
• Wolska H, Kleniewska DKJ. Successful desensitization in case of solar urticaria with sensitivity to UVA and positive passive transfer test. Derm Beruf Umwelt. 1982;30:84–6.
   PubMedGoogle Scholar